id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-317519-yhzv2yjs	Barzilai, Nir	Geroscience in the Age of COVID-19	2020-07-23		.txt	text/plain	2594	107	36	Development and use of drugs like rapamycin and metformin by the at-risk population, notably older adults, may confer broad health benefits by targeting multiple aspects of biological aging and in this way raise the chances that these people can ward off the worst effects of COVID-19. Randomized, controlled clinical trials to assess the ability of rapamycin, metformin and other potential geroprotective drugs [20] , to boost response to an eventual COVID-19 vaccine in the elderly, as well as protect against COVID-19 infection altogether, could have a substantial impact on survival in vulnerable populations and should be pursued. Often, in older patients, multiple aging-related diseases are affected by multiple risk factors, further increasing the disability and mortality. The COVID-19 global emergency has emphasized to vast masses of people the vital need to prevent old-age multimorbidity, protect the elderly and improve their health span.	./cache/cord-317519-yhzv2yjs.txt	./txt/cord-317519-yhzv2yjs.txt